FDA Issues Policy on Remote Ophthalmic Assessment and Monitoring Devices During Pandemic

The U.S. Food and Drug Administration has issued a new guidance to help expand remote ophthalmic assessment and monitoring devices during the COVID-19 pandemic, according to a press release.

The AAO has previously recommended that ophthalmologists stop routine care and only treat urgent cases. Remote assessment will allow providers to care for patients while limiting potential exposure to the virus.

The policy will remain in effect until the public health emergency is over.

Read the full guidance here.